Qiagen Adds Ebeling to Supervisory Board
23 February 2021 - - German sample and assay technologies provider Qiagen (NYSE: QGEN) has appointed Thomas Ebeling as a member of the company's supervisory board with immediate effect, the company said.

Ebeling joins Qiagen as part of a process launched by the supervisory board in 2020 to further complement and enhance the board's already extensive experience in Life Sciences and diagnostics.

The addition of Ebeling brings the number of current supervisory board members to eight.

Ebeling has been an advisor in recent years to various businesses after having served as the CEO of the German media group ProSiebenSat Media (OTC: PBSFY) from 2009 to 2018.

Prior to that, he worked for the global healthcare company Novartis (NYSE: NVS) from 1997 to 2008, including roles as CEO of Novartis Pharmaceuticals and also as CEO of Novartis Consumer Health.

He began his career in 1987 and held various positions in marketing and sales in the consumer goods industry before joining Novartis.

Ebeling, who has a degree in psychology from the University of Hamburg, has previously served on the supervisory boards of Bayer AG (OTC: BAYZF) and Lonza AG (OTC: LZAGF).